Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX12 | P18054 | 4/20 | 0.58 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.46 |
| ▸ | CYP19A1 | P11511 | 7/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.42 |
| ▸ | ESR1 | P03372 | 3/20 | 0.41 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | TTR | P02766 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | SLCO2B1 | O94956 | 1/20 | 0.40 |
| ▸ | SHBG | P04278 | 1/20 | 0.40 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL131547 | 1.00 | ALOX12 (0.58) | ALOX12PTPN1ALOX15CYP19A1KCNH2 | |
| SCHEMBL13923932 | 0.93 | CYP19A1 (0.53) | ALOX12PTPN1ALOX15CYP19A1KCNH2 | |
| SCHEMBL14281987 | 0.93 | CYP19A1 (0.53) | ALOX12PTPN1ALOX15CYP19A1KCNH2 | |
| SCHEMBL12825176 | 0.86 | ALOX12 (0.65) | ALOX12PTPN1ALOX15CYP19A1ESR1 | |
| SCHEMBL29412620 | 0.86 | ALOX12 (0.65) | ALOX12PTPN1ALOX15CYP19A1ESR1 | |
| SCHEMBL678189 | 0.86 | ALOX12 (0.65) | ALOX12PTPN1ALOX15CYP19A1ESR1 | |
| SCHEMBL13640753 | 0.82 | PTPN1 (0.56) | ALOX12PTPN1ALOX15CYP19A1ESR1 | |
| SCHEMBL15070036 | 0.82 | ALOX12 (0.60) | ALOX12PTPN1ALOX15CYP19A1KCNH2 | |
| SCHEMBL14177142 | 0.80 | CYP19A1 (0.57) | ALOX12ALOX15CYP19A1KCNH2TRPV1 | |
| SCHEMBL5797926 | 0.78 | ALOX12 (0.75) | ALOX12ALOX15CYP19A1KCNH2TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2526941-A1 | Anti-inflammatory Modalities | Marshall Edwards, Inc. (US) | 2012-11-28 | — | — | EP | disclosed |
| US-20120059176-A1 | ANTI-INFLAMMATORY MODALITIES | MARSHALL EDWARDS, INC. (US) | 2012-03-08 | — | — | US | disclosed |
| US-20120059176-A1 | ANTI-INFLAMMATORY MODALITIES | MARSHALL EDWARDS, INC. (US) | 2012-03-08 | — | — | US | disclosed |
| US-7906554-B2 | Combination chemotherapy compositions and methods | NOVOGEN RESEARCH PTY LTD (AU) | 2011-03-15 | — | — | US | disclosed |
| US-7906554-B2 | Combination chemotherapy compositions and methods | NOVOGEN RESEARCH PTY LTD (AU) | 2011-03-15 | — | — | US | disclosed |
| US-20100152284-A1 | PREVENTION AND REVERSAL OF CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY | NOVOGEN RESEARCH PTY LTD (AU) | 2010-06-17 | — | — | US | disclosed |
| US-20100152284-A1 | PREVENTION AND REVERSAL OF CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY | NOVOGEN RESEARCH PTY LTD (AU) | 2010-06-17 | — | — | US | disclosed |
| US-20090233999-A1 | COMPOSITIONS AND THERAPEUTIC METHODS INVOLVING ISOFLAVONES AND ANALOGUES THEREOF | NOVOGEN RESEARCH PTY LTD (AU) | 2009-09-17 | — | — | US | disclosed |
| US-20090233999-A1 | COMPOSITIONS AND THERAPEUTIC METHODS INVOLVING ISOFLAVONES AND ANALOGUES THEREOF | NOVOGEN RESEARCH PTY LTD (AU) | 2009-09-17 | — | — | US | disclosed |
| US-20090233999-A1 | COMPOSITIONS AND THERAPEUTIC METHODS INVOLVING ISOFLAVONES AND ANALOGUES THEREOF | NOVOGEN RESEARCH PTY LTD (AU) | 2009-09-17 | — | — | US | disclosed |
| US-20080014249-A1 | Compositions and therapeutic methods involving isoflavones and analogues thereof | NOVOGEN RESEARCH PTY LTD. | 2008-01-17 | — | — | US | disclosed |
| US-20080014249-A1 | Compositions and therapeutic methods involving isoflavones and analogues thereof | NOVOGEN RESEARCH PTY LTD. | 2008-01-17 | — | — | US | disclosed |
| US-20080014249-A1 | Compositions and therapeutic methods involving isoflavones and analogues thereof | NOVOGEN RESEARCH PTY LTD. | 2008-01-17 | — | — | US | disclosed |
| EP-1721903-A1 | Compositions and therapeutic methods involving isoflavones and analogues thereof | Novogen Research Pty. Ltd. (AU) | 2006-11-15 | — | — | EP | disclosed |
| EP-1210341-B1 | COMPOSITIONS AND THERAPEUTIC METHODS INVOLVING ISOFLAVONES AND ANALOGUES THEREOF | NOVOGEN RES PTY LTD (AU) | 2006-08-02 | — | — | EP | disclosed |
| US-20060106220-A1 | Compositions and therapeutic methods involving isoflavones and analogues thereof | NOVOGEN RESEARCH PTY. LTD. | 2006-05-18 | — | — | US | disclosed |
| US-20040147551-A1 | Compositions and therapeutic methods involving isoflavones and analogues thereof | NOVOGEN RESEARCH PTY LTD. | 2004-07-29 | — | — | US | disclosed |
| EP-1210341-A4 | COMPOSITIONS AND THERAPEUTIC METHODS INVOLVING ISOFLAVONES AND ANALOGUES THEREOF | NOVOGEN RES PTY LTD (AU) | 2003-06-11 | — | — | EP | disclosed |
| EP-1210341-A1 | COMPOSITIONS AND THERAPEUTIC METHODS INVOLVING ISOFLAVONES AND ANALOGUES THEREOF | Novogen Research Pty. Ltd. (AU) | 2002-06-05 | — | — | EP | disclosed |
| WO-2001017986-A1 | COMPOSITIONS AND THERAPEUTIC METHODS INVOLVING ISOFLAVONES AND ANALOGUES THEREOF | NOVOGEN RESEARCH PTY LTD (AU) | 2001-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152284-A1 | PREVENTION AND REVERSAL OF CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY | PMP22, NGF, GAP43 | ALOX12 990/4885PTPN1 3046/4885ALOX15 965/4885 |
| US-20060106220-A1 | Compositions and therapeutic methods involving isoflavones and analogues thereof | SHBG, OAT, APOB | ALOX12 1633/4885PTPN1 2937/4885ALOX15 1586/4885 |
| US-20080014249-A1 | Compositions and therapeutic methods involving isoflavones and analogues thereof | SHBG, ESR2, GPER1 | ALOX12 1886/4885PTPN1 2163/4885ALOX15 1841/4885 |
| US-20120059176-A1 | ANTI-INFLAMMATORY MODALITIES | TNF, PTGES, NFKBIA | ALOX12 61/4885PTPN1 2468/4885ALOX15 72/4885 |
| US-20090233999-A1 | COMPOSITIONS AND THERAPEUTIC METHODS INVOLVING ISOFLAVONES AND ANALOGUES THEREOF | SHBG, OAT, APOB | ALOX12 1633/4885PTPN1 2937/4885ALOX15 1586/4885 |
| US-20040147551-A1 | Compositions and therapeutic methods involving isoflavones and analogues thereof | SHBG, ESR2, GPER1 | ALOX12 2013/4885PTPN1 2130/4885ALOX15 2078/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.